# TMDX — AI stock forecast & analysis

> AI-generated analysis by K3vl4r — 2026-07-29. Informational only, not financial advice.

**Recommendation:** HOLD

**Scores (0–100):** Overall 5.8 · Fundamentals 6.2 · Technicals 5.8 · Growth 7.8 · Risk 7.8

## Summary

TMDX is a category-leading organ preservation platform with elite underlying unit economics (45% ROE, 59% GM, 30% TTM sales growth) but faces a binary Aug 4 earnings print in ~6 days where a four-quarter operating margin collapse (23.2%→7.6%) and FCF flip to -$12M must reverse. Price at $76.29 has broken modestly above the $65-$75 range but sits 51% below the 52W high with 23% short float and options pricing a ~15% move — this is a HOLD into the print, with any pre-earnings sizing treated as speculation, not investment.

## Price targets (6-month horizon)

- Bear: $60.00
- Base: $82.00
- Bull: $100.00

## News context

The signal in the recent news flow is that the sell-side has moderated but remains constructive: TD Cowen reiterated Buy with a $120 PT, Evercore lowered from $100 to $90 but kept Outperform, and Piper Sandler is at $120 highlighting the $2.2B US kidney opportunity. Consensus target sits at $112.89 with a Recom score of 1.64 (strong buy skew). A Seeking Alpha piece explicitly frames the thesis as 'The Margins Must Recover,' which mirrors our own bear/bull pivot point. Motley Fool and others frame the -45% drawdown as a growth-at-reasonable-price opportunity. The noise: the class-action litigation flagged in deep research and generic 'affordable growth stock' takes. The single most actionable news item is the confirmed Aug 4 AMC earnings date — everything else is context. Social sentiment is split 50/50, with retail explicitly noting that straddles are pricing a >15% move, confirming the binary event risk.

## About
- Methodology: https://app.k3vl4r.com/methodology
- Full report: https://app.k3vl4r.com/r/tmdx-ai-stock-forecast-04d40530610165a34fae0a6f4340c913
- AI-generated; model outputs can be wrong. Not financial advice.